CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.41), $0.88 better than the analyst estimate of ($2.29). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.12 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.